Enbrel All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37
Amgen (July 29, 2014)
PFIZER REPORTS SECOND-QUARTER 2014 RESULTS
Pfizer (July 29, 2014)
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
Coherus BioSciences (July 16, 2014)
Global Biological Drugs Market is Expected to Reach USD 287,139.7 Million in 2020: Transparency Market Research (July 16, 2014)
CEL-SCI Receives $225,000 NIH Research Grant to Develop Rheumatoid Arthritis Treatment
CEL-SCI (July 15, 2014)
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease
Protalix BioTherapeutics (June 18, 2014)
AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
Bristol-Myers Squibb (June 10, 2014)
Ironwood Pharmaceuticals Appoints Douglas Williams, Ph.D., to Board of Directors
Ironwood Pharmaceuticals (June 04, 2014)
Oncos Therapeutics Recruits Dr Magnus Jaderberg as CMO to Strengthen its Focus on Cancer Immunotherapy
Oncos Therapeutics (June 04, 2014)
Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis
Pfizer (May 23, 2014)

Displaying 10 out of a possible 611 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2010/11

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2010 2011 2011
Enbrel2 7,257 7,892 +9%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel4 393

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now